Salarius Pharmaceuticals, Inc. and VolitionRx Limited announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q(R) technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q(R) has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4791 USD | +5.27% | -1.66% | -26.29% |
Mar. 25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
Mar. 25 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.29% | 1.96M | |
+26.03% | 49.18B | |
+0.92% | 42.11B | |
+49.90% | 40.37B | |
-5.26% | 28.85B | |
+13.28% | 26.09B | |
-22.21% | 18.71B | |
+8.81% | 13.26B | |
+32.25% | 12.32B | |
+0.39% | 11.99B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement